-
Product Insights
NewNet Present Value Model: BioNTech SE’s MVT-5873
Empower your strategies with our Net Present Value Model: BioNTech SE's MVT-5873 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BNT-321 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-321 in Solid Tumor Drug Details: MVT-5873 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BNT-321 in Metastatic Adenocarcinoma of The Pancreas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BNT-321 in Metastatic Adenocarcinoma of The Pancreas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BNT-321 in Metastatic Adenocarcinoma of The Pancreas Drug Details:...
-
Product Insights
Contrast Agents Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Contrast Agents Pipeline Market Report Overview The Contrast Agents pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Positron Emitting Tomography Contrast Agents ·       Magnetic Resonance Imaging (MRI) Contrast Agents ·       Gadolinium-based MRI Contrast Agents...
-
Company Profile
Myovant Sciences Ltd – Company Profile
Myovant Sciences Ltd (Myovant), a subsidiary of Sumitovant Biopharma Ltd, is a biopharmaceutical company that develops and commercializes new treatments for women’s diseases and endocrine disorders. The company’s products include relugolix, an oral small molecule that functions as a gonadotropin-releasing hormone receptor antagonist targeting conditions such as heavy menstrual bleeding associated with uterine fibroids. In addition, it also offers MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of the hormonal preparation in assisted reproduction. The...
Add to Basket -
Product Insights
Microvascular Therapeutics LLC Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Microvascular Therapeutics LLC Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Microvascular Therapeutics LLC (MVT) is a biotechnology company which has developed a new, improved, patented, ultrasound contrast agent via the MVT-100. The company has products for molecular imaging and theragnostic for cancer and heart disease. MVT is headquartered in Tucson, Arizona, the US. GlobalData's Medical Devices company profile report, “Microvascular Therapeutics LLC Pipeline Insight and Competitive Landscape, 2023" provides...
-
Product Insights
Net Present Value Model: MVT-5873
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model MVT-5873 Drug Details MVT-5873 is under...
-
Product Insights
Colon Cancer Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Colon Cancer Global Clinical Trials Review, H1, 2017" provides an overview of Colon Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Colon Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Female Infertility – Opportunity Analysis and Forecasts to 2028
Female infertility (FI) is a complex disorder defined as the inability to conceive after at least one year of timed, unprotected intercourse. The etiology of the condition spans a wide range of disorders that can be broadly classified into the following categories: diminished ovarian reserve & ovulation disorders, endometriosis, fallopian tube abnormalities, uterine factors and unexplained infertility. Several factors may be considered before a treatment decision is made, including treatment effectiveness (live birth rate), treatment burden (such as number of...